Stifel raises Checkpoint Software stock price target on revenue outlook

Stifel raised its Check Point Software price target to $148 from $130 but maintained a Hold rating; the new target is just above the cited share price of $144.48. Management expects subscription revenue to sustain double-digit growth and exceed $1.5 billion by fiscal 2027, while citing memory-price, foreign-exchange and sales-and-marketing cost pressures. Recent third-quarter non-GAAP EPS of $2.49 matched forecasts, while revenue of $669.8 million missed by about $2.3 million; the company said product revenue likely reached a low point, but recovery may be gradual.

Analysis

CHKP’s key issue is conversion, not headline profitability: if subscription growth accelerates while product revenue stabilizes, recurring mix can improve revenue visibility and support a higher-quality earnings multiple. But the path may be margin-dilutive first—higher memory costs pressure appliance economics while added sales and marketing spend is required to win renewals and expand accounts. A high reported gross margin does not establish that these incremental costs are immaterial.

Over the next 1–3 months, the test is whether product revenue actually bottoms and subscription growth sustains double digits; another revenue miss or cautious guidance would reinforce the view that the recovery is slower than management’s stated ambition. Over 6–18 months, appliance cost inflation could also raise customer prices or slow refresh cycles, creating openings for software-led rivals such as CrowdStrike and Zscaler, while Palo Alto Networks and Fortinet compete for broader platform budgets. The opportunity for CHKP is that subscription conversion could offset hardware cyclicality, but that requires evidence in reported growth and retention—not management confidence alone.

The target increase offers little apparent catalyst on its own: it leaves the analyst’s valuation close to the cited share price, while neither that target nor third-party fair-value estimates verify durable growth. The contrarian risk is that investors may overfocus on near-term product weakness if subscription economics are improving; conversely, treating a product-revenue low point as a recovery is premature until confirmed by subsequent results.

Key Decisions for Investors

• No immediate directional trade: the article provides no verified valuation, consensus-growth, or subscription-retention data to support a high-conviction long or short. Treat the analyst target revision as a weak signal rather than a catalyst.
• Watch the next earnings release for subscription growth, product revenue, gross-margin trajectory, and sales-and-marketing expense. Consider a long only if subscription growth remains double digit and product revenue stabilizes without further margin deterioration.
• Use a relative-value short thesis only if subsequent results show renewed product weakness or rising cost pressure without subscription acceleration; compare CHKP with PANW, FTNT, CRWD, and ZS after checking valuation and growth expectations rather than assuming those peers are uniformly better positioned.
• Falsifiers: sustained product-revenue recovery and improving margin despite memory and FX pressure would weaken the cautious thesis; another revenue shortfall, reduced subscription-growth expectations, or deterioration in gross margin would strengthen it.